Atara Biotherapeutics (ATRA) Cost of Revenue (2023 - 2026)

Atara Biotherapeutics (ATRA) has 4 years of Cost of Revenue data on file, last reported at $124000.0 in Q1 2026.

• Quarterly Cost of Revenue fell 99.39% year-over-year to $124000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $897000.0 (down 97.73% YoY) and the FY2025 annual result came in at $21.2 million, up 0.97% from the prior year.
• Cost of Revenue advanced to $124000.0 in Q1 2026, from $104000.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $20.4 million in Q1 2025 to a low of $104000.0 in Q4 2025.
• A 4-year average of $3.9 million and a median of $2.6 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2025 — Cost of Revenue surged 929.67% — and 2026, when it tumbled 99.39%.
• Tracing ATRA's Cost of Revenue over 4 years: stood at $3.2 million in 2023, then surged by 115.03% to $6.8 million in 2024, then tumbled by 98.47% to $104000.0 in 2025, then grew by 19.23% to $124000.0 in 2026.
• The last three Cost of Revenue figures came in at $124000.0 (Q1 2026), $104000.0 (Q4 2025), and $115000.0 (Q3 2025), per Business Quant data.